all rights reserved © science photo
Researchers at the University of Michigan have identified a promising new drug compound for targeting one of the most aggressive types of breast cancer. The compound, currently called UM-164, goes after a kinase known to play a role in the growth and spread of triple-negative breast cancer. UM-164 blocks the kinase c-Src and inhibits another pathway, p38, involved in this subtype. The researchers found that the compound had very few side effects in mice.
You can read the full article on UofMHealth.org here.
Leave a Reply